Teligent saw revenues plunge by a third and suffered a $140m operating loss last year, after its longstanding failure to lift a US Food and Drug Administration warning letter against its key manufacturing facility in Buena, New Jersey continued to buckle operations.
The US-based player’s profit and loss statement included a $79.8m write-down of the Buena facility – the majority of impairment...







